Bispecific antibody · Immune activation, directed at B-cell maturation antigen (TNFRSF17) and CD3 · developed by AbbVie
Etentamig is a T-cell engaging bispecific IgG4 monoclonal antibody that binds BCMA on malignant plasma cells and CD3 on cytotoxic T-lymphocytes. By redirecting these T-cells to BCMA-expressing tumor cells, it induces their killing. It is studied in multiple myeloma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07728188 | Phase 3 | Relapsed or Refractory Multiple Myeloma | Recruiting | ABBV |
| NCT05650632 | Phase 1 | Multiple Myeloma | Recruiting | ABBV |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Multiple Myeloma
See ABBV's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
ABBV catalysts and pipeline →